Cancer Biologist Joan Massagué Named Director of the Sloan Kettering Institute

Pictured: Joan Massagué

New Sloan Kettering Institute Director Joan Massagué

Renowned cancer biologist Joan Massagué has been named Director of the Sloan Kettering Institute, one of the most dynamic and robust cancer research programs in the United States, and the research arm of Memorial Sloan Kettering Cancer Center. Dr. Massagué, Chair of the Cancer Biology and Genetics Program at Memorial Sloan Kettering, succeeds Thomas J. Kelly. Dr. Massagué will assume his new position on January 1, 2014.

 “Dr. Massagué is an exemplary scientist and an international leader in the study of cancer metastasis and the growth factors that regulate cell behavior. He is one of Memorial Sloan Kettering’s most vital, imaginative, and collaborative members,” says Craig B. Thompson, President and CEO of Memorial Sloan Kettering. “He led the Sloan Kettering Institute’s Cell Biology Program and its Cancer Biology and Genetics Program, successively – and brilliantly – even as his own research was advancing.

“I am delighted that he will now lead the Sloan Kettering Institute, confident that he will do so with great distinction,” Dr. Thompson adds. “The breadth of Dr. Massagué’s expertise and his superb ability to bring people together will ensure that the Sloan Kettering Institute continues to flourish and remains one of the world’s preeminent research institutions.”

The Sloan Kettering Institute was established in 1945 by philanthropist Alfred P. Sloan and inventor Charles F. Kettering with the vision of harnessing the latest research techniques to conquer cancer. With a research staff that today includes more than 100 laboratory investigators, 550 research fellows, and 260 graduate students — and with $184 million in grants and contracts revenue — the Institute leads the way in biomedical research, frequently translating scientific advances into innovative clinical applications, including the development of nine FDA-approved drugs.

“I am honored beyond words by the trust Memorial Sloan Kettering has placed in me to lead the Sloan Kettering Institute and serve it in its quest to bring top-quality science to bear on solving the problem of cancer,” says Dr. Massagué. “We have many of the most gifted scientists and one of the best science programs in the nation. I look forward to cultivating this rich diversity of research disciplines in order to maximize their impact on the research, education, and patient care missions of the institution at large.

“One of the attractions of this position is that it involves thinking about where science is going, where the Sloan Kettering Institute should be going, and planning for an exciting future,” Dr. Massagué adds.  “I am eager to work with my colleagues to move forward the frontiers of cancer biomedical research.”

Career and Research Contributions

Joan Massagué was born in Barcelona, Spain, in 1953. He earned his PhD in pharmacy and biochemistry from the University of Barcelona in 1978 and completed a postdoctoral fellowship at Brown University in 1982 in the laboratory of Michael P. Czech, where he determined the structure of the receptor for the hormone insulin. Later that year, he became an assistant professor in biochemistry at the University of Massachusetts.

In 1989, he joined Memorial Sloan Kettering as the Chair of the Sloan Kettering Institute’s Cell Biology Program and in 2003 was named inaugural Chair of the Cancer Biology and Genetics Program. Dr. Massagué has been a Howard Hughes Medical Institute investigator for the past 24 years, and is the incumbent of the Alfred P. Sloan Chair at Memorial Sloan Kettering.

With a research career spanning more than 30 years, Dr. Massagué has been lauded for the originality and importance of his work elucidating the mechanism of action for transforming growth factor-beta (TGF-β) signaling. The TGF-β family of proteins plays a key role in the proliferation and differentiation of many different cell types, controlling the formation and regeneration of tissues from embryonic life to adulthood.

Because the proteins can both inhibit and activate cell growth, breakdowns in TGF-β activity cause cancer in adults as well as serious birth defects. In cancer, TGF-β can act as a tumor suppressor in early stages of cancer and as a promoter of the spread of cancer in the later stages of tumor progression. To find ways to prevent and treat such disorders, Dr. Massagué and his group are determining the molecular processes by which TGF-β exerts its control on the growth and behavior of diverse cell types.

More recently, Dr. Massagué’s primary research interests involve how growth factors, signaling pathways, and gene expression programs control cancer cell metastasis — the process by which cancer spreads from one part of the body to another. Metastasis is the cause of 90 percent of deaths from cancer, yet until recently, little was known about its underlying mechanisms.

Dr. Massagué’s lab has probed the basic causes of metastasis in a number of different cancers – such as breast, lung, and kidney cancer – and identified genes and pathways that give tumor cells the specialized traits they need to infiltrate specific organs, survive in them, and spawn new tumors. This work could lead to innovative approaches to treat cancer that would prevent cancers from spreading rather than eliminating established tumors.

Dr. Massagué has authored more than 300 scientific articles and has been one of the most-cited researchers in all areas of science in the past two decades. In addition, he has mentored and trained more than 100 graduate students and postdoctoral fellows.

Back to top

Honors and Awards

A member of the Institute of Medicine and the National Academy of Sciences, Dr. Massagué has received numerous honors and awards, including the King Juan Carlos I Research Award (1993); the Prince of Asturias Award in Science and Technology (2004); the Vilcek Prize for Biomedical Research (2006); the Passano Laureate Award (2007); the G.H.A. Clowes Memorial Award from the American Association for Cancer Research (2009); the Frontiers of Knowledge Award in Biomedicine from the BBVA Foundation (2009); the Feodor Lynen Medal (2010); the Pasarow Award for Cancer Research (2011); and the Italian American Cancer Foundation Prize (2013).

Back to top


Commenting is disabled for this blog post.

I have been a patient of Dr.Modi on a research study. I am now back in my home town getting the drug which was approved by FDA this year. Would I qualify for this type of research when this drug no longer works?

Judith, you should talk with Dr. Modi about whether you might be eligible for any other research studies. Thank you for your comment.

Dear Dr. Massa
Congratulations on your recent appointment. Thank you for your commitment to your work and to the mission of MSKCC. You remind me very much of your colleague, Dr. Peter Steinherz whose own research and life-time career at MSKCC proved essential in my son's surving both ALL and its treatment from 1978 to 1981. My son is alive and well, employed as, he likes to say, a "transportational engineer", happily married, and has a heart of gold. I am a modest financial contributor to MSKCC and am glad to think that it goes to help MSKCC in its pursuit of conquering cancer.
Best wishes,
Harry Kuhn, PhD(c), MSW, LCSW

Perdone Dr. Massagué, le podría hacer llegar esta nota al Dr Larry Norton? Es que no sé su dirección de correo.... Muchas gracias!! y enhorabuena por todo lo que están haciendo por todos los enfermos. Muchas gracias.
Hola Dr. Norton : Mi nombre es Pilar Medina, fui paciente suya en Julio 1996, tenía 34 años y padecía cáncer de mama con metástasis en el pulmón. Soy de Sevilla España (paciente del Dr. Hernán Cortés-Funes). Estuve en el Memorial Sloan y me operó la Dra. Valerie Rush. En España el tratamiento era operación y altas dosis de quimioterapia más autotrasplante. Ud. sabiamente después de operarme, me dijo q no me diera la quimioterapia, que esperara a q salieran drogas nuevas, porque este tratamiento de autotrasplantes en mujeres jóvenes no era efectivo. Actualmente estoy con Zoladex trimestral desde 1996. Llevo casi 18 años... Sigo con el Dr. Cortés-Funes en España, pero me acuerdo mucho de Ud. y quería decirle con este mensaje que existen ángeles en la tierra y uno de ellos se llama Dr. Larry Norton. Muchas gracias por todo lo que hace en su lucha contra el cáncer. Muchas gracias Dr. Norton. No hay palabras para decirle lo mucho que estoy agradecida. Un saludo muy fuerte y todos mis mejores deseos.

Mi nombre es Pilar Medina, de Sevilla. Enhorabuena al Dr. Massagué por su nombramiento y por su trabajo. No le conozco, pero soy paciente del Dr. Hernán Cortés y fui paciente también del Dr. Larry Norton y sé todo lo que vale. Muchas gracias por dedicarse a este trabajo y aportar toda su sabiduría para que nos podamos curar. Muchas gracias!!!

As a former Postdoc at Massague's lab, I know that Joan is a great choice to lead this magnificent institution, CONGRATULATIONS!!!!!

Dear Joan,

My name is Miguel Ubilluz, from Lima, Perú, I am 59 years old.

I had and emergency operation of colon cancer back in October 2014, stage II.

Thereafter received 6 months of Chemotherapy

On the latest, Feb 2017, Pet CT a 9mm tumor in my right lung has been found which retained 3,3 SUV.

Can a metastatic lung tumor be developed without developing a liver tumor first?

Thanks very much.

Dear Miguel, we’re sorry to hear about your diagnosis. Although spread of colon cancer to the lung is less common than spread to the liver, this can occur in about 10-20% of patients. Because the cancer spreads through the bloodstream, it’s possible for the cancer to be in the lung without spreading to the liver first. Thank you for your comment, and best wishes to you.